Ulrich Schäfer (Hamburg, Germany) speaks to Cardiovascular News at EuroPCR (21–24 May, Paris) about the VIVALL study which looked at the safety and efficacy of the replacement of failed surgical bioprosthetic aortic valves with the Allegra Transcatheter Heart Valve (NVT).
Schäfer says the Allegra device achieved “very good haemodynamic outcomes” and showed a reduction in gradient from 35 to 11.2 mm of mercury.
The Allegra device “met the primary safety endpoint” and provided a “nice haemodynamic reduction in gradient” despite a “very demanding patient population”.
Schäfer also touches on why the Allegra device is different to other TAVI devices on the market including that “besides being self-expanding, it carries a different mode of implantation” and a shorter stent design that “might also allow for better coronary access”.
This video is sponsored by NVT.